Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS
Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS
This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.
Inclusion Criteria:
Exclusion Criteria:
Bogota, Cundinamarca, Colombia
Maroussi Athens, 15126, Greece
Putrajaya, Kuala Lumpur 62250, Malaysia
Rajathevee, Bangkok 10400, Thailand
Amphoe Muang, Chiang Mai 50200, Thailand
Muang District, Khonkaen 40002, Thailand